- Home
- AACG vs SRZN Comparison
AACG vs SRZN Comparison
Compare AACG & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- SRZN
- Stock Information
- Founded
- AACG 1999
- SRZN 2015
- Country
- AACG China
- SRZN United States
- Employees
- AACG N/A
- SRZN N/A
- Industry
- AACG Other Consumer Services
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- AACG Real Estate
- SRZN Health Care
- Exchange
- AACG Nasdaq
- SRZN Nasdaq
- Market Cap
- AACG 31.9M
- SRZN 38.1M
- IPO Year
- AACG N/A
- SRZN N/A
- Fundamental
- Price
- AACG $0.84
- SRZN $10.57
- Analyst Decision
- AACG
- SRZN
- Analyst Count
- AACG 0
- SRZN 0
- Target Price
- AACG N/A
- SRZN N/A
- AVG Volume (30 Days)
- AACG 24.5K
- SRZN 49.1K
- Earning Date
- AACG 11-07-2024
- SRZN 11-06-2024
- Dividend Yield
- AACG N/A
- SRZN N/A
- EPS Growth
- AACG N/A
- SRZN N/A
- EPS
- AACG N/A
- SRZN N/A
- Revenue
- AACG $35,747,843.00
- SRZN $10,000,000.00
- Revenue This Year
- AACG N/A
- SRZN N/A
- Revenue Next Year
- AACG N/A
- SRZN N/A
- P/E Ratio
- AACG N/A
- SRZN N/A
- Revenue Growth
- AACG 15.80
- SRZN N/A
- 52 Week Low
- AACG $0.50
- SRZN $6.00
- 52 Week High
- AACG $1.65
- SRZN $16.19
- Technical
- Relative Strength Index (RSI)
- AACG 36.73
- SRZN 54.47
- Support Level
- AACG $0.70
- SRZN $9.50
- Resistance Level
- AACG $0.92
- SRZN $11.27
- Average True Range (ATR)
- AACG 0.06
- SRZN 1.10
- MACD
- AACG -0.01
- SRZN 0.01
- Stochastic Oscillator
- AACG 48.28
- SRZN 41.36
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments are Overseas art study services, Other educational services and K-12 education assessment and other services. Majority of its revenue comes from Overseas art study services.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).